Diabetes Care:产后体重滞留可增加代谢性疾病风险

2014-04-29 完美事业 丁香园

妊娠期体重增加20%以上是一种正常的生理现象。分娩后,母体恢复正常体重的调节能力可被生活方式等诸多因素破坏,包括缺乏锻炼、戒烟和睡眠时间有限。因此,妊娠和产后体重滞留可明显改变妇女长期体重增加模式。实际上,与妊娠期增加的体重相比,产后1年体重能更好的预测女性15年后超重可能性。【原文下载】 女性产后体重滞留的累积效应可能会导致心脏代谢疾病风险增加。但是,由于缺少评估产前/产后体重变化与心血管

妊娠期体重增加20%以上是一种正常的生理现象。分娩后,母体恢复正常体重的调节能力可被生活方式等诸多因素破坏,包括缺乏锻炼、戒烟和睡眠时间有限。因此,妊娠和产后体重滞留可明显改变妇女长期体重增加模式。实际上,与妊娠期增加的体重相比,产后1年体重能更好的预测女性15年后超重可能性。【原文下载】

女性产后体重滞留的累积效应可能会导致心脏代谢疾病风险增加。但是,由于缺少评估产前/产后体重变化与心血管/代谢危险因素关系的研究资料,几乎没直接的证据支持这一假设。

针对这个问题,来自加拿大西奈山医院的Kew等进行了一项研究,试图评价产后第一年体重变化的心脏代谢含义,以及它的时间效应。研究结果发表在近期的Diabetes Care上。

研究人员对妊娠期招募的305名妇女妊娠期、产后3月和12月的心脏代谢特征进行评估。根据孕前与产后3月体重变化比较,以及产后3月与12月体重变化比较情况(体重减轻或增加),将参与者分为4组:体重减轻/体重减轻,体重增加/体重减轻,体重减轻/体重增加,体重增加/体重增加。

结果显示,与孕前相比,大多数女性(81.0%)产后3月体重增加;而产后3-12月间,大多数女性(74.4%)体重减轻。 产后3月时,各组经校正的LDL胆固醇和载脂蛋白-B(apo B)均值略有差别,但是校正后的血压、空腹和2h血糖、HDL、甘油三酯、稳态模型评估的胰岛素抵抗指数(HOMA-IR)、乙二腈和C-反应蛋白没有显著性差异。

但是产后12月时,上述指标出现明显的梯度变化,从体重均减轻组到体重减轻/体重增加再到体重均增加组,校正后的舒张压、HOMA-IR、LDL和apoB逐渐升高。同样地, 校正后的乙二腈均值在不同组间逐渐降低。

结果表明,分娩后3-12月体重没有明显下降的女性最早在产后1年就会出现不良心脏代谢特征。提示产后3-12月是一个关键的时期,期间医生和患者都应注意,体重控制对于女性长期代谢和心血管疾病都可能具有重要作用。

原始出处:


Kew S1, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R.Cardiometabolic Implications of Postpartum Weight Changes in the First Year After Delivery.Diabetes Care. 2014 Mar 25.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989570, encodeId=4da119895e024, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jun 27 06:24:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636852, encodeId=e1f516368520c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 20 02:24:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759434, encodeId=2bf01e59434da, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 29 15:24:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901203, encodeId=9af1190120379, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Feb 27 21:24:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472941, encodeId=31ae14e294197, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu May 01 02:24:00 CST 2014, time=2014-05-01, status=1, ipAttribution=)]
    2014-06-27 sodoo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989570, encodeId=4da119895e024, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jun 27 06:24:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636852, encodeId=e1f516368520c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 20 02:24:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759434, encodeId=2bf01e59434da, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 29 15:24:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901203, encodeId=9af1190120379, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Feb 27 21:24:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472941, encodeId=31ae14e294197, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu May 01 02:24:00 CST 2014, time=2014-05-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1989570, encodeId=4da119895e024, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jun 27 06:24:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636852, encodeId=e1f516368520c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 20 02:24:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759434, encodeId=2bf01e59434da, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 29 15:24:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901203, encodeId=9af1190120379, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Feb 27 21:24:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472941, encodeId=31ae14e294197, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu May 01 02:24:00 CST 2014, time=2014-05-01, status=1, ipAttribution=)]
    2014-09-29 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1989570, encodeId=4da119895e024, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jun 27 06:24:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636852, encodeId=e1f516368520c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 20 02:24:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759434, encodeId=2bf01e59434da, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 29 15:24:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901203, encodeId=9af1190120379, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Feb 27 21:24:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472941, encodeId=31ae14e294197, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu May 01 02:24:00 CST 2014, time=2014-05-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1989570, encodeId=4da119895e024, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jun 27 06:24:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636852, encodeId=e1f516368520c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 20 02:24:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759434, encodeId=2bf01e59434da, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 29 15:24:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901203, encodeId=9af1190120379, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Feb 27 21:24:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472941, encodeId=31ae14e294197, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu May 01 02:24:00 CST 2014, time=2014-05-01, status=1, ipAttribution=)]

相关资讯

低钠浓度透析液对一周三次夜间血液透析患者的影响

文献标题:Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement stud

Nat Rev Cardiol:戒烟降低非糖尿病患者心血管疾病风险

吸烟者总是借口戒烟会引起体重增加,而体重增加对心血管的坏处和继续吸烟一样多,不过,这个借口将不再成立。2013年3月13日发表于JAMA的前瞻性社区队列研究提示,尽管吸烟者在戒烟后短期内体重会有所增加,但他们发生心血管事件的风险只有继续吸烟者的一半,与长期戒烟者风险相近。研究者表示“如果能量化戒烟引起的增重与实际心血管疾病风险的关联,医生可以更好地劝说患者戒烟。”研究分析了弗明汉后代研究中3,25

Arch Gen Psychiatry:抗精神病药物治疗导致严重的体重增加的相关基因

抗精神病药物越来越多地在美国人群中运用,但抗精神病药物会带来一系列副作用包括体重迅速增加,尤其是对儿童而言在Zucker Hillside医院和Feinstein医学研究中心的研究人员发现了一种基因与常用的抗精神病药物治疗引发的体重增加有关。这些研究结果发表在Archives of General Psychiatry杂志上。 这项研究针对第二代抗精神病药物开展。对第二代抗精神病药物是常用来治疗